Literature DB >> 32291238

Epigenetic Biomarkers in Gallbladder Cancer.

Pramod K Tiwari1.   

Abstract

Gallbladder cancer (GBC) is associated with various nongenetic and genetic factors. Lack of specific and sensitive diagnostic markers has significantly impacted the mortality of this disease. Here we discuss the recent discovery of epigenetic changes that show great promise as diagnostic biomarkers as well as potential therapeutic targets for GBC.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biomarker; epigenetic; gallbladder cancer; lncRNA; methylation; miRNA

Mesh：

Substances：

Year:  2020        PMID： 32291238     DOI： 10.1016/j.trecan.2020.03.003

Source DB:  PubMed          Journal:  Trends Cancer        ISSN： 2405-8025


  6 in total

1.  Ubiquitin-specific protease 3 facilitates cell proliferation by deubiquitinating pyruvate kinase L/R in gallbladder cancer.

Authors:  Ruo-Peng Liang; Xiao-Xue Zhang; Jie Zhao; Rong-Tao Zhu; Wei-Jie Wang; Qin-Wei Lu; Yu-Ling Sun
Journal:  Lab Invest       Date:  2022-09-30       Impact factor: 5.502

2.  Long noncoding RNA PVT1 promoted gallbladder cancer proliferation by epigenetically suppressing miR-18b-5p via DNA methylation.

Authors:  Longyang Jin; Qiang Cai; Shouhua Wang; Shuqing Wang; Jiandong Wang; Zhiwei Quan
Journal:  Cell Death Dis       Date:  2020-10-16       Impact factor: 8.469

3.  ARRB1 Drives Gallbladder Cancer Progression by Facilitating TAK1/MAPK Signaling Activation.

Authors:  Xudong Zhang; Zhijun Kong; Xiaoliang Xu; Xiao Yun; Jiadeng Chao; Dong Ding; Tao Li; Yuan Gao; Naifu Guan; Chunfu Zhu; Xihu Qin
Journal:  J Cancer       Date:  2021-01-30       Impact factor: 4.207

4.  Mining of RNA Methylation-Related Genes and Elucidation of Their Molecular Biology in Gallbladder Carcinoma.

Authors:  Changhong Yang; Jialei Chen; Zhe Yu; Jing Luo; Xuemei Li; Baoyong Zhou; Ning Jiang
Journal:  Front Oncol       Date:  2021-02-25       Impact factor: 6.244

5.  Common DNA methylation changes in biliary tract cancers identify subtypes with different immune characteristics and clinical outcomes.

Authors:  Zhiquan Qiu; Jun Ji; Yu Xu; Yan Zhu; Bin Li; Chunfang Gao; Guoqiang Wang; Chengcheng Li; Yuzi Zhang; Jing Zhao; Chenyang Wang; Xiaofang Wen; Zhou Zhang; Bingsi Li; Zhihong Zhang; Shangli Cai; Xiaoqing Jiang
Journal:  BMC Med       Date:  2022-02-07       Impact factor: 8.775

6.  Primary Hepatoid Adenocarcinoma of Gallbladder With MB21D2/GALNT12/ARID2 Mutations: A Case Report.

Authors:  Zhenyu Li; Qingming Jiang; Xinyu Chen; Yu Xiao; Jue Xiao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-03       Impact factor: 5.555
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.